Search results
Showing 1051 to 1065 of 7680 results
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.
Evidence-based recommendations on quizartinib (Vanflyta) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia in adults.
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)
Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA774)
NICE is unable to make a recommendation on lenalidomide (Revlimid) for treating relapsed or refractory mantle cell lymphoma. This is because Celgene did not provide an evidence submission.
Show all sections
Sections for TA774
Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)
Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.